July 24, 2020

An Open Letter to our Stakeholders from our Interim Board Chair and CEO

As you may know, Indivior has announced an agreementto resolve criminal charges and civil complaints related to SUBOXONE® (buprenorphine and naloxone) Film.

We are pleased to resolve this matter in a way that enables us to continue progressing toward our vision that all patients around the world have access to evidence-based treatment for the chronic conditions and co- occurring disorders of addiction. Specifically, we believe the agreement provides greater certainty for all Indivior stakeholders, including the patients around the world who are prescribed our medicines.

We want to emphasize that the matter that we have resolved occurred well in the past and does not reflect the values Indivior has strived to demonstrate and uphold during our long history of partnering with healthcare providers, policy makers and communities to fight the opioid crisis.

On behalf of Indivior and its employees, we want to thank all our partners for their support and their continued efforts in the fight against the opioid crisis. We are honored to serve alongside you.

Sincerely,

Daniel Tassé

Mark Crossley

Interim Chair

Chief Executive Officer

Attachments

  • Original document
  • Permalink

Disclaimer

Indivior plc published this content on 24 July 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 July 2020 14:55:03 UTC